On Apr. 6, 2020, Luminex announced announced that the FDA has issued an Emergency Use Authorization for its ARIES SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19.

The assay runs on the ARIES System, an FDA-cleared, sample-to-answer, automated, on-demand molecular diagnostic platform. The system is capable of running up to 144 tests per day, requiring no specialty training and minimal human interaction.